Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411526 · ClinicalTrials.gov registry record · Phase 1
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
A Phase 1 study, sponsored by Zogenix.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02411526: Completed Phase 1 study, sponsored by Zogenix.
NCT02411526 is a Phase 1 study that has completed, run by Zogenix. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02411526, a Phase 1 study, has completed, sponsored by Zogenix.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
Interventions
- DRUG Oral Risperidone
- DRUG Risperdal Consta
- DRUG ZX003 (Risperidone-SABER®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
What the finished NCT02411526 record still lists
NCT02411526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Oral Risperidone is the first listed.
NCT02411526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02411526 about?
NCT02411526 is a clinical study titled "Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia". This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
What is the current status of trial NCT02411526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02411526?
The interventions under investigation include: Oral Risperidone (DRUG), Risperdal Consta (DRUG), ZX003 (Risperidone-SABER®) (DRUG).
Who is sponsoring clinical trial NCT02411526?
This trial is sponsored by Zogenix, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02411526's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia